This competitive renewal proposal is directed at determining which cells from the mouse immune system express 6, g and K opioid receptors, and whether activation of these cells alters the amount of receptor expressed and the distribution of the multiple opioid receptors among the different lymphocyte populations. By using fluorescent opioids and flow cytometry, we have developed a novel indirect fluorescent method for detecting about: opioid receptors. This method is more sensitive than radioreceptor binding methodology. Double-labeling experiments have shown the highest level of about receptor expression on mouse thymocytes and macrophages, and on human microglial cells. The studies proposed in this application focus on the detection of 6 and/.t opioid receptors. Based on functional studies, the first hypothesis to be tested is that mouse thymocytes and CD4+ and CD8+ T cells express ;5 opioid receptors. To detect 6 receptors, two approaches will be compared. FITC-labeled derivatives of the 6-selective ligand, naltrindole, will be used in a manner similar to the labeling of the receptor with the FITC-conjugated K ligand. The second approach will use specific antibodies directed against the 6 receptor. The second hypothesis to be tested is that mouse peritoneal and T cells express the/,t opioid receptor. The g receptor will be labeled with either a FITC-labeled derivative of fentanyl or morphine, and/or antibodies directed against the la opioid receptor. Flow cytometry will be used to detect the labeled receptors. For both 6 and g receptors, the goal is to develop an optimal method for detecting the receptor, and then to use this method to study receptor expression. The third hypothesis is that activation of lymphocytes will increase the expression of opioid receptors since levels of receptor mRNA have been shown to increase with cell activation. Collectively, these studies will use an innovative approach and technique to determine which cells from the immune express about:, 6, and about opioid receptors and if receptor expression is altered with activation of the cells. These studies will lay the foundation for determining the cellular mechanisms by which opioids alter immune function and immunological responses to viral infection, including AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004355-12
Application #
6515389
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
Sharp, Charles
Project Start
1989-08-01
Project End
2004-06-30
Budget Start
2002-07-01
Budget End
2003-06-30
Support Year
12
Fiscal Year
2002
Total Cost
$279,125
Indirect Cost
Name
University of Rochester
Department
Pharmacology
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Parkhill, Amy L; Bidlack, Jean M (2006) Reduction of lipopolysaccharide-induced interleukin-6 production by the kappa opioid U50,488 in a mouse monocyte-like cell line. Int Immunopharmacol 6:1013-9
Bidlack, Jean M; Khimich, Maxim; Parkhill, Amy L et al. (2006) Opioid receptors and signaling on cells from the immune system. J Neuroimmune Pharmacol 1:260-9
Gekker, Genya; Hu, Shuxian; Wentland, Mark P et al. (2004) Kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells. J Pharmacol Exp Ther 309:600-6
Bidlack, J M; Abraham, M K (2001) Mitogen-induced activation of mouse T cells increases kappa opioid receptor expression. Adv Exp Med Biol 493:103-10
Martin-Kleiner, I; Bidlack, J M (2001) Chronic opioid treatment of the mouse thymoma cell lines R1.G1 and R1EGO leads to down-regulation of the kappa opioid receptor without desensitization of adenylyl cyclase activity. Int Immunopharmacol 1:13-20
Peterson, P K; Gekker, G; Lokensgard, J R et al. (2001) Kappa-opioid receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes. Biochem Pharmacol 61:1145-51
Bidlack, J M (2000) Detection and function of opioid receptors on cells from the immune system. Clin Diagn Lab Immunol 7:719-23
Ignatowski, T A; Bidlack, J M (1999) Differential kappa-opioid receptor expression on mouse lymphocytes at varying stages of maturation and on mouse macrophages after selective elicitation. J Pharmacol Exp Ther 290:863-70
Martin-Kleiner, I; Bidlack, J M (1999) The synthetic kappa-opioid agonist (-)U50,488 does not affect calcium transport into R1.1 mouse thymoma cell line. Int J Immunopharmacol 21:133-40
Ignatowski, T A; Bidlack, J M (1998) Detection of kappa opioid receptors on mouse thymocyte phenotypic subpopulations as assessed by flow cytometry. J Pharmacol Exp Ther 284:298-306

Showing the most recent 10 out of 24 publications